RxDoctor Payments Data

David Harris, MD

Ophthalmology · Knoxville, TNNPI 1356346910

Payments from drug & device makers

$3,399in general payments, 2019–2025

Across 104 payments — averaging $32.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$903
  • Johnson & Johnson Surgical Vision, Inc.$586
  • Tarsus Pharmaceuticals, Inc.$275
  • Glaukos Corporation$262
  • Mallinckrodt Hospital Products Inc.$224
  • AbbVie$219
  • plus $930 from 17 others

What the payments were for

  • Food & beverage$3,399100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,399 in reported general payments places this provider in the 65th percentile of 323 ophthalmology providers in Tennessee.

See all ophthalmology providers in Tennessee

Medicare billing

Part B allowed, 2024
$383,126
Medicare patients
943
Services billed
2,745

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxervateCenegermin-Bkbj13$365,489
RestasisCyclosporine71$71,072
Prednisolone Acetate886$35,919
RocklatanNetarsudil Mesylat/Latanoprost35$20,641
CombiganBrimonidine Tartrate/Timolol59$17,787
Fluorometholone229$16,634
Cyclosporine17$15,438
LumiganBimatoprost23$10,785
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat577$10,570
ZirganGanciclovir21$9,770
Dexamethasone Sodium Phosphate242$8,349
Minocycline Hcl454$6,288
SimbrinzaBrinzolamide/Brimonidine Tart27$6,224
Latanoprost595$5,928
ValacyclovirValacyclovir Hcl116$5,136

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Dompe US, Inc.Oxervate$63$365,48913 claims
AbbVieRestasis, Combigan, Lumigan, Alphagan P$219$104,377166 claims
Aerie Pharmaceuticals, Inc.Rocklatan$12$20,64135 claims
Bausch & Lomb Americas Inc.Zirgan$58$9,77021 claims
AlconSimbrinza$903$6,22427 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 323 ophthalmology providers in Tennessee.

Other ophthalmology in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →